Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294141 | 1.00 | POLB (0.56) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL6439569 | 1.00 | POLB (0.56) | POLBCNR2MEN1CYP1A2KMT2A | |
| Sulfurous Acid SCHEMBL5567229 | 0.94 | CNR2 (0.54) | POLBCNR2MEN1CYP1A2KMT2A | |
| Sulfurous Acid SCHEMBL28752565 | 0.94 | CNR2 (0.54) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL7300117 | 0.84 | HDAC2 (0.51) | CNR2MEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL3024846 | 0.83 | POLB (0.59) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL3024849 | 0.83 | POLB (0.59) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL19099236 | 0.80 | POLB (0.63) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL14701618 | 0.80 | POLB (0.63) | POLBCNR2MEN1CYP1A2KMT2A | |
| SCHEMBL7674546 | 0.79 | POLB (0.67) | POLBCNR2MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183443-B2 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2007-02-27 | — | — | US | disclosed |
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2005-09-29 | — | — | US | disclosed |
| CN-1646477-A | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS BV (NL) | 2005-07-27 | — | — | CN | disclosed |
| EP-1492760-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP Assets B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003087033-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | ADH1C, ADH1A, ADH5 | POLB 225/4885CNR2 4217/4885MEN1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.